Systemic therapy of cancer: facts and expectations
Abstract
Background: Systemic therapy of cancer had its first major expansion in the second half of the 20th century with the development of chemotherapy and hormonal therapy. Some cancers, like leukemias, lymphomas, osteosarcoma and testicular cancer became highly curable irrespective of anatomic size – stage of the disease. Other more common cancers, such as breast cancer, colon cancer, ovarian cancer, lung cancer and prostate cancer became on a larger scale curable in the early stages of the disease while in the advanced stages of the disease long term remissions could be achieved by chemotherapy and/or hormonal therapy.
Conclusions: Cancer patients nowadays live longer and with a better quality of life. With mapping of the human genom, possibilities for determining and identifying the cancer genom became available at the turn of the last century. The era of molecular oncology which enables personalized treatment tailored to each patient and his tumor is now upon us. Molecular oncology makes it possible to identify the molecular targets and to develop therapy which targets them. In addition it gives us more knowledge about the prognostic as well as predictive markers. Good examples of effective targeted cancer therapy are treatment of GIST with imatinib and treatment of HER2+ breast cancer with trastuzumab. In both cases the target as well as the patients were precisely selected. Experience from various trastuzumab trials teach us that targeted therapy will also be the most effective in the early stages of cancer, when the burden of the disease is quite limited. Treatment of advanced cancer with targeted treatment so far mostly results in remissions but not cure. Numerous additional new targeted therapies are currently under development and by no doubt they will very soon allow us to facilitate the selection of proper treatment at proper time for proper patients. In contrast to empirical treatment approaches, a personalized one enables the best possible treatment for each individual patient and also decreases the cost of treatment in a society. This kind of an approach requires a much closer collaboration between clinician and other members of the multidisciplinary team, especially with a molecular oncologist/pathologist, availability of drugs and a large ammount of knowledge and experience by the leading molecular oncologist and medical oncologist.
Downloads
References
DeVitta VT, Hellman S, Rosenberg SA, eds. Cancer-principles and practice of oncology. Philadelphia: Lippincot; 2005.
Cavalli F, Hansen HH, Kaye SB, eds. Textbook of medical oncology. 3rd ed. London: Martin Dunitz Ltd.; 2005.
Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetja bolnikov z rakom v Sloveniji – Cancer patients survival in Slovenia 1983– 1997. Ljubljana: Onkološki inštitut; 2003.
Early Breast Cancer Trialisis’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: on overview of the randomised trials. Lancet 2005; 365: 1687–717.
Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3: 540–1.
Fizazi K. A multitargeted approach: clinical advances in the treatment of solid tumours. Ann Oncol 2007; 18 Suppl 10: 1427–587.
Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nature Rev Drug Discav 2003; 38: 566–80
Snoj N, Čufer T. Biološko in tarčno zdravljenje karcinomov. Onkologija 2007: 11: 72–6.
Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17: 280–6.
Piccart-Gebhart MJ. Adjuvant trastuzumab therapy for HER2overexpressing breast cancer: What we know and what we still need to learn. EJC 2006; 42: 1715–9.
Cruz JJ. Targeting receptor tyrozine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007; 18: 421–30.
Punglia TRS, Winer EP, Weeks JC, Burstein HJ. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. ASCO meeting 2007 proceedings. 2007, Abstract 502.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.